← FDA DRUG APPROVALS

FDA NDA · NDA011284

MEPROSPAN

Sponsor: MEDPOINTE PHARM HLC

APPLICATION
NDA011284
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

MEPROSPANDiscontinued
MEPROBAMATE 400MG · CAPSULE, EXTENDED RELEASE · ORAL
MEPROSPANDiscontinued
MEPROBAMATE 200MG · CAPSULE, EXTENDED RELEASE · ORAL
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →